Immunotherapy has emerged as a promising treatment for cancer, with immune checkpoint inhibitors (ICIs) dominating the market. The market is projected to grow due to the rise in the prevalence of diseases, the increase in the adoption of combination therapies, the surge in the funding for new therapies, and the approval of innovative therapies. Numerous opportunities within the realm of immune therapies exist, considering the increasing prevalence of several diseases. Moreover, there is a notable upswing in funding for developing innovative therapies and a rising trend in novel immunotherapies approval.
Emergence of Novel Immune-Mediated Therapies
AIKey Takeways
- Immune therapies offer a great source of hope for patients but are typically expensive, substantially contributing to the rising healthcare costs.
- Upcoming immune therapies will be the majority for oncology indications, followed by infectious and autoimmune indications.
- Multiple clinical trials are actively underway, examining the potential synergistic benefits of combining immunotherapy with other treatment modalities.
Share
Download Whitepaper
Related Ins(AI)ghts
Related Tags
About SG Analytics
SG Analytics is a leading global data solutions firm providing data-centric research and contextual analytics services to its clients, including Fortune 500 companies, across the Financial Services, Technology, Media & Entertainment, and Healthcare sectors. Established in 2007 and a Great Place to Work certified company, SGA has over 1600 employees and has a presence across the US, the UK, Switzerland, Poland, and India.
Besides being recognized by analyst firms such as Gartner, Everest Group, and ISG, SGA has been part of the elite Deloitte Technology Fast 50 India 2024 and APAC (Asia Pacific) 2025 High Growth Companies by the Financial Times & Statista.